BCR and B-cell chronic lymphocytic leukemia: Additionally, CLL clones differ in their responsiveness to BCR engagement, with surrogate antigen binding, e.g., interaction with anti-IG antibodies, being more effective in stimulating U-CLL than M-CLL cases (21–23), and the ability to deliver a signal via the BCR correlating with worse clinical outcomes (24, 25).